

Agreement #169528



**FIFTH AMENDMENT TO OREGON HEALTH AUTHORITY
2021-2023 INTERGOVERNMENTAL AGREEMENT FOR THE
FINANCING OF PUBLIC HEALTH SERVICES**

In compliance with the Americans with Disabilities Act, this document is available in alternate formats such as Braille, large print, audio recordings, Web-based communications and other electronic formats. To request an alternate format, please send an e-mail to dhs-oha.publicationrequest@state.or.us or call 503-378-3486 (voice) or 503-378-3523 (TTY) to arrange for the alternative format.

This Fifth Amendment to Oregon Health Authority 2021-2023 Intergovernmental Agreement for the Financing of Public Health Services, effective July 1, 2021, (as amended the “Agreement”), is between the State of Oregon acting by and through its Oregon Health Authority (“OHA”) and Tillamook County, (“LPHA”), the entity designated, pursuant to ORS 431.003, as the Local Public Health Authority for Tillamook County. OHA and LPHA are each a “Party” and together the “Parties” to the Agreement.

RECITALS

WHEREAS, OHA and LPHA wish to modify the set of Program Element Descriptions set forth in Exhibit B of the Agreement

WHEREAS, OHA and LPHA wish to modify the Fiscal Year 2022 (FY22) Financial Assistance Award set forth in Exhibit C of the Agreement.

WHEREAS, OHA and LPHA wish to modify the Exhibit J information required by 2 CFR Subtitle B with guidance at 2 CFR Part 200;

NOW, THEREFORE, in consideration of the premises, covenants and agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

AGREEMENT

1. This Amendment is effective on January 1, 2022, regardless of the date this amendment has been fully executed with signatures by every Party and when required, approved by the Department of Justice. However, payments may not be disbursed until the Amendment is fully executed.

2. The Agreement is hereby amended as follows:

a. Exhibit A “Definitions”, Section 18 “Program Element” is amended to add Program Element titles and funding source identifiers as follows:

| PE NUMBER AND TITLE • SUB-ELEMENT(S) | FUND TYPE | FEDERAL AGENCY/ GRANT TITLE | CFDA# | HIPAA RELATED (Y/N) | SUB-RECIPIENT (Y/N) |
|--|------------------|---|--------------|----------------------------|----------------------------|
| <u>PE 10-02</u> Sexually Transmitted Disease (STD) | FF | CDC/Preventive Health Services - Sexually Transmitted Diseases Control Grants | 93.977 | N | Y |

b. Exhibit B Program Element #10 “Sexually Transmitted Disease” is hereby superseded and replaced in its entirety by Attachment A attached hereto and incorporated herein by this reference.

c. Section 1 of Exhibit C of the Agreement, entitled “Financial Assistance Award” for FY22 is hereby superseded and replaced in its entirety by Attachment B, entitled “Financial Assistance Award (FY22)”, attached hereto and incorporated herein by this reference. Attachment B must be read in conjunction with Section 3 of Exhibit C.

d. Exhibit J of the Agreement entitled “Information required by 2 CFR Subtitle B with guidance at 2 CFR Part 200” is amended to add to the federal award information datasheet as set forth in Attachment C, attached hereto and incorporated herein by this reference.

3. LPHA represents and warrants to OHA that the representations and warranties of LPHA set forth in Section 4 of Exhibit F of the Agreement are true and correct on the date hereof with the same effect as if made on the date hereof.

4. Capitalized words and phrases used but not defined herein shall have the meanings ascribed thereto in the Agreement.

5. Except as amended hereby, all terms and conditions of the Agreement remain in full force and effect.

6. This Amendment may be executed in any number of counterparts, all of which when taken together shall constitute one agreement binding on all parties, notwithstanding that all parties are not signatories to the same counterpart. Each copy of this Amendment so executed shall constitute an original.

IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the dates set forth below their respective signatures.

7. Signatures.

STATE OF OREGON, ACTING BY AND THROUGH ITS OREGON HEALTH AUTHORITY

Signature: _____

Name: /for/ Nadia A. Davidson

Title: Director of Finance

Date: _____

TILLAMOOK COUNTY LOCAL PUBLIC HEALTH AUTHORITY

Signature: _____

Printed Name: _____

Title: _____

Date: _____

DEPARTMENT OF JUSTICE – APPROVED FOR LEGAL SUFFICIENCY

Approved by Wendy Johnson, Senior Assistant Attorney General on July 27, 2021. Copy of emailed approval on file at OHA, OC&P.

REVIEWED BY OHA PUBLIC HEALTH ADMINISTRATION

Signature: _____

Name: Derrick Clark (or designee)

Title: Program Support Manager

Date: _____

Attachment A
Program Element Description

Program Element #10: Sexually Transmitted Diseases (STD) Client Services

OHA Program Responsible for Program Element:

Public Health Division/Center for Public Health Practice/HIV, STD and TB Section

1. **Description.** Funds provided under this Agreement for this Program Element may only be used in accordance with, and subject to, the requirements and limitations set forth below, to deliver Sexually Transmitted Diseases (STD) Client Services. ORS 433.006 and OAR 333-019-0000 assign responsibility to LPHAs for sexually transmitted disease (STD) investigations and implementation of STD control measures within an LPHA's service area. STD client services may include, but are not limited to, Case finding, Partner Services (i.e., contact tracing), clinical and laboratory services, and education and outreach activities. The funds provided for STD client services under the Agreement for this Program Element may only be used as supplemental funds to support LPHA's STD investigations and control efforts and are not intended to be the sole funding for LPHA's STD client services program.

STDs are a significant health problem in Oregon, with over 22,000 new Cases reported every year. STDs pose a threat to immediate and long-term health and well-being. In addition to increasing a person's risk for acquiring and transmitting HIV infection, STDs can lead to severe reproductive health complications, including poor pregnancy outcomes. Protecting the population from communicable disease by reducing rates of gonorrhea and early syphilis is a public health priority and is included in Healthier Together Oregon, the State Health Improvement Plan.

This Program Element, and all changes to this Program Element are effective the first day of the month noted in Issue Date section of Exhibit C Financial Assistance Award unless otherwise noted in Comments and Footnotes of Exhibit C of the Financial Assistance Award.

2. **Definitions Specific to Sexually Transmitted Diseases (STD) Client Services.**

- a. **Case:** An individual who has been diagnosed by a health care provider, as defined in OAR 333-017-0000, as having a reportable disease, infection, or condition, as described in OAR 333-018-0015, or whose illness meets defining criteria published in OHA's Investigative Guidelines.
- b. **Case Investigation:** A process that includes identifying Cases, conducting a Case interview, collecting and reporting Core Variables, and providing Partner Services.
- c. **Contact:** Sexual partner of STD Case.
- d. **Core Variables:** Variables required by OHA and the CDC cooperative agreement PS19-1901 Strengthening STD Prevention and Control for Health Departments (STD PCHD) that are essential for counting and/or investigating reported Cases accurately and for describing trends in reported Cases in key populations at the local and state level.
- e. **Disease Intervention Specialist:** Job title used to identify to staff person(s) trained to deliver HIV/STD Partner Services.

- f. In-Kind Resources:** Tangible goods or supplies having a monetary value that is determined by OHA. Examples of such In-Kind Resources include goods such as condoms, lubricant packages, pamphlets, and antibiotics for treating STDs. If the LPHA receives In-Kind Resources under this Agreement in the form of medications for treating STDs, LPHA must use those medications to treat individuals for STDs as outlined in Section 4.j. of this Program Element. In the event of a non-STD related emergency, with notification to the OHA STD program, the LPHA may use these medications to address the emergent situation. If the LPHA self-certifies as a 340B STD clinic site and receives reimbursement for 340B medications from OHA, they shall ensure these medications are used in accordance with the Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs regulations regarding “340B Drug Pricing Program.”
- g. Investigative Guidelines:** OHA reportable disease guidelines, which are incorporated herein by this reference.
- h. Partner Services:** Partner Services refers to a continuum of clinical evaluation, counseling, diagnostic testing, and treatment designed to increase the number of infected persons brought to treatment and reduce transmission among sexual networks. Partner Services includes conducting Case interviews to identify sex and needle-sharing partners, offering to conduct partner notification, providing STD/HIV testing (or referrals) to all contacts, and referring Cases and Contacts to HIV PrEP and additional medical/social services, including treatment.
- i. Priority Gonorrhea Cases:** Gonorrhea Cases requiring Case Investigation, defined as Cases among pregnant or pregnancy-capable individuals, Cases among individuals co-infected with HIV; and rectal gonorrhea Cases.
- j. Priority Syphilis Cases:** Syphilis Cases requiring Case Investigation, defined as Cases staged as primary, secondary, and early non-primary non-secondary syphilis and Cases of any syphilis stage among pregnant or pregnancy-capable individuals.
- k. Reportable STDs:** A Reportable STD refers to diagnosed or suspected Cases of Chancroid, Chlamydia, Gonorrhea, and Syphilis, as further described in Division 18 of OAR Chapter 333, and HIV, as further described in ORS Chapter 433.
- l. STD Outbreak:** The occurrence of an increase in Cases of previously targeted priority disease type in excess of what would normally be expected in a defined community, geographical area or season, and, by mutual agreement of the LPHA and OHA, exceeds the expected routine capacity of the LPHA to address.
- m. Technical Assistance:** Services of OHA HIV/STD Prevention staff to support the LPHA’s delivery of STD Client Services, which include providing training and during STD Case Investigations and STD Outbreak response.

3. **Alignment with Modernization Foundational Programs and Foundational Capabilities.** The activities and services that the LPHA has agreed to deliver under this Program Element align with Foundational Programs and Foundational Capabilities and the public health accountability metrics (if applicable), as follows (see [Oregon’s Public Health Modernization Manual](http://www.oregon.gov/oha/PH/ABOUT/TASKFORCE/Documents/public_health_modernization_manual.pdf), (http://www.oregon.gov/oha/PH/ABOUT/TASKFORCE/Documents/public_health_modernization_manual.pdf):

a. **Foundational Programs and Foundational Capabilities** (As specified in Public Health Modernization Manual)

| Program Components | Foundational Program | | | | | Foundational Capabilities | | | | | | |
|---|----------------------|---------------------------------|----------------------|-------------------|---|--|---|-----------------------------------|-----------------------------|-------------------|----------------|-------------------------------------|
| | CD Control | Prevention and health promotion | Environmental health | Population Health | Access to clinical preventive services Direct services | Leadership and organizational competencies | Health equity and cultural responsiveness | Community Partnership Development | Assessment and Epidemiology | Policy & Planning | Communications | Emergency Preparedness and Response |
| <i>Asterisk (*) = Primary foundational program that aligns with each component</i> | | | | | <i>X = Foundational capabilities that align with each component</i> | | | | | | | |
| <i>X = Other applicable foundational programs</i> | | | | | | | | | | | | |
| Epidemiological investigations that report, monitor and control Sexually Transmitted Diseases and HIV. | * | | | | | | X | | X | | | |
| STD client services (screening, testing, treatment, prevention). | * | | | | X | | X | | X | | | |
| Condom and lubricant distribution. | * | | | | | | X | X | | | | |

b. **The work in this Program Element helps Oregon’s governmental public health system achieve the following Public Health Accountability Metric:**

Gonorrhea rates

c. **The work in this Program Element helps Oregon’s governmental public health system achieve the following Public Health Modernization Process Measure:**

- (1) Percent of gonorrhea Cases that had at least one contact that received treatment; and
- (2) Percent of gonorrhea Case reports with complete “priority” fields. As used herein, priority fields are defined as: race, ethnicity, gender of patient’s sex partners, HIV status or date of most recent HIV test, and pregnancy status for females of childbearing age (15-44).

- 4. Procedural and Operational Requirements.** By accepting and using the Financial Assistance awarded under this Agreement and for this Program Element, LPHA agrees to conduct activities in accordance with the following requirements:
- a.** Train and maintain at least one staff to act as a Disease Intervention Specialist (DIS), as described in its local staffing plan, which has been approved by OHA. OHA shall make available CDC-training to LPHAs needing to train staff as a DIS.
 - b.** Use funds for this Program Element in accordance with its local program budget, which has been approved by OHA. Modification to the local program budget may only be made with OHA approval.
 - c.** Allowable budget expenses are:
 - (1)** Personnel costs including fringe for at least one staff acting as a DIS. Personnel costs for additional staff beyond a DIS are allowable (e.g. program manager, epidemiologist, public health nurse) provided the additional staff are supporting the role and function of a DIS and HIV/STD Case Investigations. Additional staff shall not exceed the FTE dedicated to the DIS position.
 - (2)** Travel (including mileage, lodging, per diem). Client transportation (e.g. taxi vouchers, gas cards) are an allowable expense provided the purpose is to facilitate STD testing, treatment, and other Case Investigation activities.
 - (3)** Supplies and equipment needed to carry out the work of a DIS. Equipment is defined as costing \$5,000 or greater and having a useful life of at least one year.
 - (4)** Other allowable expenses including postage, software and other licenses (e.g. Accurant), printing costs for educational/outreach materials, and other expenses approved by the STD Program on a case-by-case basis.
 - (5)** Indirect costs to a maximum allowable rate of 10%.
 - d.** Unallowable expenses include but are not limited to:
 - (1)** Medications and screening/testing costs
 - (2)** Harm reduction supplies including syringes
 - (3)** Cash or gift card incentives (outside of taxi vouchers or gas cards as outlined in Section 4.c.(2)).
 - (4)** Advertising or marketing
 - (5)** Purchase or maintenance of vehicles
 - e.** Pending availability of funds, OHA may provide the following items to the LPHA in-kind: STD medications, gift card incentives, condoms, lubricant, rapid HIV test kits, rapid syphilis test kits, coverage of certain lab fees through the Oregon State Public Health Laboratory.
 - f.** LPHA must attend any training webinars and Case review meetings required by OHA. Travel costs associated with attendance at any in-person meetings or trainings is an allowable budget expense

- g.** LPHA acknowledges and agrees that the LPHA bears the primary responsibility, as described in Divisions 17, 18, and 19, of Oregon Administrative Rules (OAR) Chapter 333, for identifying potential STD Outbreaks within LPHA’s service area, for preventing the incidence of STDs within LPHA’s service area, and for reporting in a timely manner (as required in Section 6.a.) the incidence of Reportable STDs within LPHA’s service area (as described below in Reporting Requirements). LPHA must fulfill the following minimum Case Investigation expectations described below:
- (1)** HIV: Case Investigation should be completed for each HIV Case assigned to the LPHA by the OHA HIV Surveillance Program.
 - (2)** Syphilis: Case Investigation should be completed for all Priority Syphilis Cases below at minimum. Other syphilis Cases should be investigated if there is staffing capacity or there are no Priority Syphilis Cases. OHA may require LPHA to investigate other syphilis Cases if necessitated by local epidemiology, an STD Outbreak response, or other considerations. LPHA may also independently require Case Investigation for other syphilis Cases. Priority Syphilis Cases include:
 - (a)** All primary, secondary, and early non-primary non secondary syphilis Cases regardless of sex/gender or age
 - (b)** All Cases among pregnant or pregnancy-capable individuals regardless of stage. Pregnant individuals that don’t meet the Case definition may require treatment verification. Refer to the OHA Syphilis Investigative Guidelines.
 - (3)** Gonorrhea: Case Investigation should be completed for all Priority Gonorrhea Cases below at minimum. Other gonorrhea Cases should be investigated if there is staffing capacity or there are no Priority Gonorrhea Cases. OHA may require LPHA to investigate other gonorrhea Cases if necessitated by local epidemiology, an STD Outbreak response, or other considerations. LPHA may also independently require Case Investigation for other gonorrhea Cases. Priority Gonorrhea Cases include:
 - (a)** All rectal gonorrhea Cases
 - (b)** All Cases among pregnant or pregnancy-capable individuals
 - (c)** All Cases among individuals co-infected with HIV
 - (4)** Chlamydia: Case Investigation for chlamydia Cases is not expected and may be pursued at the discretion of the LPHA.
- h.** LPHA must provide or refer client for STD Client Services in response to an individual seeking such services from LPHA. Clinical STD Client Services consist of screening individuals for Reportable STDs and treating Cases and their Contacts.
- i.** LPHA must provide STD Client Services including Case finding, treatment (not applicable for HIV) and prevention activities, to the extent that local resources permit, related to HIV, syphilis, gonorrhea, and chlamydia in accordance with:
- (1)** Oregon Administrative Rules (OAR), Chapter 333, Divisions 17, 18, and 19;
 - (2)** “OHA Investigative Guidelines for Notifiable Diseases” which can be found at: <http://bit.ly/OR-IG> ;
 - (3)** Oregon Revised Statutes (ORS), Chapters 431 & 433; and
 - (4)** Current “Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines,” which can be found at: <https://www.cdc.gov/std/treatment/>.

- j. OHA may provide, pursuant to this agreement, In-Kind Resources or Technical Assistance to assist LPHA in delivering STD Client Services. If LPHA receives In-Kind Resources under this Agreement in the form of medications for treating STDs, LPHA may use those medications to treat Cases or Contacts, subject to the following requirements:
 - (1) The medications must be provided at no cost to the individuals receiving treatment.
 - (2) LPHA must perform a monthly medication inventory and maintain a medication log of all medications supplied to LPHA under this Agreement. Specifically, LPHA must log-in and log-out each dose dispensed.
 - (3) LPHA must log and document appropriate disposal of medications supplied to LPHA under this Agreement which have expired and thereby, prevent their use.
 - (4) If the LPHA self certifies as a 340B STD clinic site and receives reimbursement for 340B medications from OHA, they must only use “340B medications” to treat individuals for STDs in accordance with the Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs regulations regarding the 340B Drug Pricing Program.
 - (5) If LPHA Subcontracts with another person to provide STD Client Services required under this Program Element, the In-Kind Resources in the form of medications received by LPHA from OHA must be provided, free of charge, to the Subcontractor for the purposes set out in this section and the Subcontractor must comply with all requirements related to such medications unless OHA informs LPHA in writing that the medications cannot be provided to the Subcontractor. The LPHA must document the medications provided to a Subcontractor under this section
 - (6) If LPHA receives In-Kind Resources under this Agreement in the form of condoms and lubricant, LPHA may distribute those supplies at no cost to individuals infected with an STD and to other individuals who are at risk for STDs. LPHA may not, under any circumstances, sell condoms supplied to LPHA under this Agreement. LPHA shall store condoms in a cool, dry place to prevent damage and shall check expiration date of condoms at least once annually.
- k. LPHA staff funded through this Agreement may be utilized to assist with Directly Observed Therapy (DOT) for Tuberculosis Services on a case-by-case basis. LPHA must discuss the staffing need with the OHA STD and TB programs and obtain written approval from both before utilizing STD staff for TB DOT.

5. General Revenue and Expense Reporting.

LPHAs receiving funding under this Financial Assistance Award must complete an “Oregon Health Authority Public Health Division Expenditure and Revenue Report” located in Exhibit C of the Agreement. These reports must be submitted to OHA each quarter on the following schedule:

| Fiscal Quarter | Due Date |
|---------------------------------|-----------------|
| First: July 1 – September 30 | October 30 |
| Second: October 1 – December 31 | January 30 |
| Third: January 1 – March 31 | April 30 |
| Fourth: April 1 – June 30 | August 20 |

6. Reporting Requirements.

- a. LPHA must review laboratory and health care provider Case reports by the end of the calendar week in which initial laboratory or physician report is made in accordance with the standards established pursuant to OAR 333-018-0020. All Cases shall be reported to the OHA HIV/STD/TB (HST) Program via Orpheus.
- b. LPHA must collect and report the Core Variables as outlined in Attachment 1. Required Core Variables are subject to change. Core Variables below that are not required for chlamydia Cases and non-Priority Gonorrhea/Syphilis Cases may be collected at the discretion of the LPHA based on local policy and capacity.

7. Performance Measures.

- a. LPHA must operate its program in a manner designed to achieve the following STD performance goals:
 - (1) Treatment with CDC-recommended gonorrhea regimen documented within 14 days of LPHA notification
 - (2) Pregnancy status documented within 14 days of LPHA notification in 100% of all female syphilis Cases under age 45
 - (3) Treatment of early syphilis with penicillin G benzathine (Bicillin) documented within 14 days of LPHA notification
 - (4) Congenital syphilis electronic report form should be completed within 45 days of birth
 - (5) Contacts should be tested/treated within 30 days before or after the index patient's testing date
- b. LPHA must operate the STD Client Services program in a manner designed to make progress toward achieving the following Oregon public health modernization process measures:
 - (1) Percent of gonorrhea Cases that had at least one Contact that received treatment
 - (2) Percent of gonorrhea Case reports with complete priority fields

Priority fields include race, ethnicity, sex of sex partner, pregnancy status, and HIV status/date of last HIV test

**Attachment 1
Required Core Variables**

| STD Core Variables | Chlamydia and Gonorrhea Cases—All | Priority Gonorrhea Cases: | Syphilis Cases—All | Priority Syphilis Cases |
|------------------------------------|--|----------------------------------|---------------------------|--------------------------------|
| Age* | ✓ | ✓ | ✓ | ✓ |
| Sex* | ✓ | ✓ | ✓ | ✓ |
| County* | ✓ | ✓ | ✓ | ✓ |
| Specimen collection date* | ✓ | ✓ | ✓ | ✓ |
| Diagnosing facility type | ✓ | ✓ | ✓ | ✓ |
| Anatomic site of infection* | ✓ | ✓ | | |
| Race/ethnicity | | ✓ | | ✓ |
| Gender identity | | ✓ | | ✓ |
| Sexual orientation | | ✓ | | ✓ |
| Sex of sex partners | | ✓ | | ✓ |
| Pregnancy status | | ✓ | ✓ | ✓ |
| HIV status | | ✓ | | ✓ |
| Treatment/Date of treatment | | ✓ | ✓ | ✓ |
| Clinical signs/symptoms | | | | ✓ |
| Substance use | | | | ✓ |
| Incarceration history | | | | ✓ |
| * Included on lab report | | | | |

| HIV Core Variables | Orpheus Tab | Reported via ELR | Entered by OHA | Entered by LPHA |
|--|---------------------------|------------------|----------------|-----------------|
| Stage | Home layout-Stage | | ✓ | |
| Status | Home layout-Status | | ✓ | |
| DOB/Age* | Home layout-Age | ✓ | ✓ | ✓ |
| Sex* | Home layout-SOGI | ✓ | ✓ | ✓ |
| Gender identity | Home layout-SOGI | | ✓ | ✓ |
| Sexual orientation | Home layout-SOGI | | ✓ | ✓ |
| Race/ethnicity | Home layout-REALD | | ✓ | ✓ |
| Pregnancy status | Home layout-Pregnant | | ✓ | ✓ |
| Housing at Dx | Home layout-Housing at Dx | | ✓ | ✓ |
| Address* | Home layout | ✓ | ✓ | ✓ |
| Phone/email | Home layout | | ✓ | ✓ |
| Diagnosing facility/Provider* | Home layout-Provider | ✓ | ✓ | ✓ |
| HARS ID HIV Diagnosis AIDS Diagnosis | Home layout | | ✓ | |
| Specimen collection date* | Labs tab | ✓ | ✓ | ✓ |
| Clinical signs/symptoms | Clinical tab | | ✓ | ✓ |
| Treatment/Date of treatment | Treatment tab | | ✓ | ✓ |
| HIV risk history At minimum: sex of partners trans partners sex for drugs/\$ substance use last neg HIV test PrEP use history STD tested | Risks tab | | ✓ | ✓ |
| Contacts | Contacts tab | | | ✓ |
| Outbreak Info | Epilinks tab | | ✓ | |
| * Included on lab report | | | | |

**Attachment B
Financial Assistance Award (FY22)**

| | | |
|---|---|---------------------------------|
| State of Oregon Oregon Health Authority Public Health Division | | |
| 1) Grantee Name: Tillamook County Street: PO Box 489 City: Tillamook State: OR Zip: 97141-0489 | 2) Issue Date Saturday, January 1, 2022 | This Action Amendment |
| | 3) Award Period From July 1, 2021 through June 30, 2022 | |

| 4) OHA Public Health Funds Approved | | | | |
|--|--|-------------------------------|----------------------------|------------------------------|
| Number | Program | Previous Award Balance | Increase / Decrease | Current Award Balance |
| PE01-01 | State Support for Public Health | \$31,495.00 | \$0.00 | \$31,495.00 |
| PE01-07 | ELC ED Contact Tracing | \$78,798.84 | \$0.00 | \$78,798.84 |
| PE01-09 | COVID-19 Active Monitoring - ELC | \$479,044.46 | \$0.00 | \$479,044.46 |
| PE01-10 | OIP - CARES | \$285,502.88 | \$0.00 | \$285,502.88 |
| PE04-02 | Community Chronic Disease Prevention | \$27,000.00 | \$0.00 | \$27,000.00 |
| PE08-01 | Ryan White B HIV/AIDS: Case Management | \$23,278.00 | \$0.00 | \$23,278.00 |
| PE08-02 | Ryan White B HIV/AIDS: Support Services | \$6,971.00 | \$0.00 | \$6,971.00 |
| PE08-03 | Ryan White B HIV/AIDS: Oral Health | \$4,294.00 | \$0.00 | \$4,294.00 |
| PE10-02 | Sexually Transmitted Disease (STD) | \$0.00 | \$30,973.00 | \$30,973.00 |
| PE12-01 | Public Health Emergency Preparedness and Response (PHEP) | \$73,171.00 | \$0.00 | \$73,171.00 |
| PE13-01 | Tobacco Prevention and Education Program (TPEP) | \$94,511.00 | \$0.00 | \$94,511.00 |
| PE40-01 | WIC NSA: July - September | \$34,255.49 | \$0.00 | \$34,255.49 |
| PE40-02 | WIC NSA: October - June | \$105,762.00 | \$0.00 | \$105,762.00 |
| PE40-05 | Farmer's Market | \$1,760.00 | \$0.00 | \$1,760.00 |

| 4) OHA Public Health Funds Approved | | | | |
|--|--|-------------------------------|----------------------------|------------------------------|
| Number | Program | Previous Award Balance | Increase / Decrease | Current Award Balance |
| PE42-03 | MCAH Perinatal General Funds & Title XIX | \$2,079.00 | \$0.00 | \$2,079.00 |
| PE42-04 | MCAH Babies First! General Funds | \$6,645.00 | \$0.00 | \$6,645.00 |
| PE42-06 | MCAH General Funds & Title XIX | \$3,901.00 | \$0.00 | \$3,901.00 |
| PE42-11 | MCAH Title V | \$20,408.00 | \$0.00 | \$20,408.00 |
| PE43-01 | Public Health Practice (PHP) - Immunization Services | \$10,800.00 | \$0.00 | \$10,800.00 |
| PE43-06 | CARES Flu | \$0.00 | \$0.00 | \$0.00 |
| PE46-05 | RH Community Participation & Assurance of Access | \$15,698.00 | \$0.00 | \$15,698.00 |
| PE50 | Safe Drinking Water (SDW) Program (Vendors) | \$39,911.00 | \$0.00 | \$39,911.00 |
| PE51-01 | LPHA Leadership, Governance and Program Implementation | \$150,842.00 | \$0.00 | \$150,842.00 |
| PE51-03 | ARPA WF Funding | \$57,993.00 | \$0.00 | \$57,993.00 |
| | | \$1,554,120.67 | \$30,973.00 | \$1,585,093.67 |

| 5) Foot Notes: | |
|-----------------------|---|
| PE01-01 | 5/1/21: Bridge funding for July-Sept 2021. Additional funds to be awarded once budgets are final. |
| PE01-01 | 9/1/21: Prior comment null and void. Funding is now for FY22 7/1/2021-6/30/2022. |
| PE01-07 | 9/1/2021: Funds are available 07/01/2021 - 06/30/2023 |
| PE01-09 | 9/1/2021: Funds are available 7/1/2021 - 06/30/2023 |
| PE01-10 | Awarded funds can be spent on allowable costs for the period of 7/1/2021 - 6/30/2024. Any unspent funds as of 6/30/22 will be rolled over into the FY23 award. Please see provided budget guidance for more details on roll over information. |
| PE40-01 | 5/2021: All SFY2022 Q1 funding award needs to be spent down by 9/30/2021. No unspent funds carryover to Q2-4 period is allowed. |
| PE40-02 | 5/2021: SFY2022 Q2-4 funds need to be spent by 6/30/2022. |

| 5) Foot Notes: | |
|-----------------------|---|
| PE40-02 | 12/2021: December grant adjustment for one-time funding. |
| PE40-05 | 7/2021: Funds will be paid in two installments in August and October of 2021. |
| PE43-06 | 9/1/2021: Activities funded under PE43-06 are the same as PE01-10. Please use PE43-06 funds first and if possible, use by 6/30/2022. No additional funds will be added to PE43-06. Current FY22 awards are a rollover of unspent FY21 awards. |
| PE51-01 | 5/1/21: Bridge funding for July-Sept 2021. Additional funds to be awarded once budgets are final. |
| PE51-01 | 9/1/21. Prior comment null and void. Award is for FY22 7/1/2021-6/30/2022. |

| 6) Comments: | |
|---------------------|--|
| PE01-07 | 12/2021: SFY22 Rollover of unspent funds from FY21 |
| PE01-09 | 9/2021: Rollover of unspent funds from FY21 to FY22 |
| PE01-10 | 9/2021: Rollover of Unspent funds 189,054.88 from FY21 to FY22 |
| PE10-02 | 1/2022: Funds must be spent by 06/30/22 |
| PE12-01 | 10/2021: SFY22 award of unspent funds from SFY21 - must be spent by 06/30/2022 and an updated Budget is required by 12/31/2021 |
| PE40-01 | 12/2021: Q1 underspent de-obligation; 5/2021: SFY2022 Q1 funding: Spend \$7,474 on Nutrition Ed, \$1,011 on BF Promotion |
| PE40-02 | 5/2021: SFY2022 Q2-4 funding: spend \$20,123 on Nutrition Ed, \$3,033 on BF Promotion. |
| PE40-05 | 07/2021: WIC FDNP Season 2021. Funds must be spent by 12/31/2021. |
| PE51-01 | 9/2021: added funding for FY22 |

| 7) Capital outlay Requested in this action: | | | | |
|--|------------------|------|-------------|--|
| Prior approval is required for Capital Outlay. Capital Outlay is defined as an expenditure for equipment with a purchase price in excess of \$5,000 and a life expectancy greater than one year. | | | | |
| Program | Item Description | Cost | PROG APPROV | |
| | | | | |
| | | | | |

Attachment C
Information required by CFR Subtitle B with guidance at 2 CFR Part 200

| PE10-02 Sexually Transmitted Disease (STD) | |
|---|---|
| Federal Award Identification Number: | NH25PS005149 |
| Federal Award Date: | 12/16/2020 |
| Budget Performance Period: | 01/01/2019-12/31/2023 |
| Awarding Agency: | Centers for Disease Control & Prevention |
| CDFA Number: | 93.977 |
| CFDFA Name: | Preventive Health Services - Sexually Transmitted Diseases Control Grants |
| Total Federal Award: | 2,975,291.00 |
| Project Description: | STD Prevention & Control |
| Awarding Official: | Cassandra Davis |
| Indirect Cost Rate: | 17.64% |
| Research and Development (T/F): | FALSE |
| PCA: | 53195 |
| Index: | 50403 |

| Agency | DUNS No. | Amount | Grand Total: |
|-----------|-----------|-------------|--------------|
| Tillamook | 060584554 | \$30,973.00 | \$30,973.00 |

| PE50 Safe Drinking Water (SDW) Program (Vendors) | | | | | | | |
|---|-------------|-------------|---|---|--|--|--|
| Federal Award Identification | State Funds | State Funds | 00031221 | 00031222 | 98009020 | 98009021 | |
| Federal Award Date: | | | 07/15/2021 | 12/10/2021 | 09/09/2020 | 09/29/2021 | |
| Budget Performance Period: | | | 10/01/2020-09/30/2022 | 10/01/2021-09/30/2022 | 10/01/2020-09/30/2023 | 10/01/2021-09/30/2024 | |
| Awarding Agency: | | | EPA | EPA | EPA | EPA | |
| CDFA Number: | | | 66.432 | 66.432 | 66.468 | 66.468 | |
| CFDFA Name: | | | State Public Water System Supervision | State Public Water System Supervision | Capitalization Grants for Drinking Water State Revolving Funds | Capitalization Grants for Drinking Water State Revolving Funds | |
| Total Federal Award: | | | 1,841,000 | 1,841,000 | 17384400 | 17,368,800.00 | |
| Project Description: | | | FFY2021 Oregon State Public Water System Supervision (PWSS) | FFY2022 Oregon State Public Water System Supervision (PWSS) | FFY 2020 Oregon's Drinking Water State Revolving Fund Capitalization Grant | FFY 2021 Oregon's Drinking Water State Revolving Fund Capitalization Grant | |
| Awarding Official: | | | Neverley Wake | Neverley Wake | Harold Rogers | Richard Green | |
| Indirect Cost Rate: | | | 17.64% | 17.64% | 17.64% | 17.64% | |
| Research and Development | FALSE | FALSE | FALSE | FALSE | FALSE | FALSE | |
| PCA: | 51283 | 51058 | 51315 | 51320 | 51987 | 51865 | |
| Index: | 50204 | 50204 | 50204 | 50204 | 50204 | 50204 | |

| Agency | DUNS No. | Amount | Amount | Amount | Amount | Amount | Amount | Grand Total: |
|-----------|-----------|-------------|------------|------------|------------|------------|------------|--------------|
| Tillamook | 060584554 | \$13,970.00 | \$3,991.00 | \$2,494.00 | \$7,483.00 | \$3,991.00 | \$7,982.00 | \$39,911.00 |